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     Nephrotic syndrome is the commonest glomerular disease. Typical symptoms could be proteinuria, low 
serum albumin and oedema. The mechanism of proteinuria in nephrotic syndrome is a defective glomerular 
filtration barrier. Renal biopsy is the gold standard for diagnosis of nephrotic syndrome currently which is 
invasive and based on histopathological features, therefore it seems to be necessary to search for noninvasive 
biomarkers to be used as the complementary tests in the diagnostics and prognostics of glomerular diseases, 
particularly when renal biopsy is limited or contraindicated. While a big proportion of urinary proteins 
originate from kidney tissue and these tissue specific proteins excrete more in kidney injury, therefore the 
identification of urinary proteins can further our understanding of renal dysfunction and renal disease 
including nephrotic syndrome. The interest of scientist to  urinary proteomics is also growing for biomarker 
discovery. This review focuses on some types of nephrotic syndrome and proteomic studies applying urine 
specimen which have been reported. 
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INTRODUCTION 
    The nephrotic syndrome is defined by a urinary 
protein level exceeding 3.5 g per 1.73 m
2
 of body-
surface area per day [1]. It is also considered as 
the triad of proteinuria, low serum albumin and 
oedema [2]. The mechanism of proteinuria in 
nephrotic syndrome is 
a defective glomerular filtration barrier. This 
barrier is impermeable to proteins in health but 
becomes permeable in nephrotic syndrome with 
the resultant loss of protein into the urine [2].  
Furthermore, Nephrotic syndrome has been 
postulated to due to an abnormality in cell 
mediated immunity, which could affect the T-
lymphocyte population, resulting in an increased 
production of lymphokines leading to increased 
glomerular filtration permeability to proteins [3]. 
Renal biopsy is the gold standard test for 
definitive diagnosis of nephrotic syndrome which 
vary in histological appearance and include: 
minimal change nephrotic syndrome (MCNS), 
focal segmental glomerulosclerosis (FSGS), 
diffuse mesangial sclerosis, mesangiocapillary 
glomerulonephritis and membranous nephropathy 
[2]. While there is no doubt that renal biopsy is 
the best and gold standard for the diagnosis of 
glomerular diseases including nephrotic 
syndrome, it is necessary to search for 
noninvasive biomarkers to be used as the 
complementary tests in the diagnostics and 
prognostics of glomerular diseases, particularly 
when renal biopsy is limited or contraindicated. 
Urinary biomarker discovery using proteomics 
tools is one of the most promising approaches for 
diagnosis and prognosis of kidney diseases. In 
this review, we imply some proteomics study 
using urine specimen for some types of nephrotic 
syndrome as well as a brief explanation regarding 
importance of urine as a valuable source of 
biomarkers. 
Importance of Urine in proteomic studies: 
    Human urine is one of the valuable biological 
fluids and there are several reasons for 
considering urine the ideal medium for 
discovering biomarkers of diseases and being 
attractive protein source for proteomic studies: (1) 
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Collecting urine sample  is noninvasive and it is 
easy to be obtained in large amounts, (2) proteins 
and peptides in urine are quite stable and less 
complex, and (3) the amount and composition of 
urinary proteome directly reflect changes in 
functions of the kidney and the urogenital tract (4) 
sampling can be repeated over time in the same 
individual for clinical surveillance [4-5]. 
Proteins in the urine are mainly composed of 
plasma proteins that pass through the glomerular 
filtration barrier as well as proteins secreted from 
the kidney and urinary tract [6]. More 
specifically, these proteins originate from 
glomerular filtration of plasma, excretion from 
epithelial cells in the urinary tract, sloughing of 
epithelial cells and casts, and formation of urinary 
exosomes [7].  
The main drawback of using urine proteomics in 
clinical applications is that the urinary proteome 
changes greatly among different individuals, and 
among the same individual under different 
physiological conditions[6]. For instance, Urine 
specimens show a high degree of variability in 
volume; protein concentration (particularly in the 
case of kidney damage or dysfunction); total 
protein excreted pH(ranges from 4-8); as well as 
variability in urine components due to age, health, 
diet, or other factors; proteolysis while the urine is 
stored in the bladder; and degradation of collected 
urine samples upon storage [8]. Therefore, 
normalization of the amount or concentration of 
protein is critical for proteomics and protein 
biomarker experiments [9]. One example of 
normalization method is calculating the ratio of 
each protein's expression to the total protein in the 
sample [10]. 
 The most important advantage of study the 
urinary proteome is the nature of noninvasiveness 
of collecting urine in comparison with biopsy. In 
addition, several factors related to the nature of 
the disease and patient status can directly impact 
on the effectiveness of renal biopsy [11] which 
they are granted using urinary proteome. For 
example, some conditions do not affect the kidney 
uniformly and the biopsy sample may not be 
representative of the disease involvement. A 
single urine specimen, sent from the ward or 
clinic to the laboratory for tests which provide 
sensitive and specific information on the disease 
process and prognosis, and also predict the 
response to treatment at an early stage of disease 
would provide the ideal [11]. 
As it was mentioned above, a big proportion of 
urinary proteins originate from kidney tissue, 
therefore the identification of urinary proteins can 
further our understanding of renal dysfunction 
and renal disease. Quantitative and qualitative 
analyses of urinary proteins have been used to 
study renal physiology and renal diseases [12-13]. 
To sum up, urinary proteomics provides a new 
direction for renal disease diagnosis, treatment, 
monitoring and prognosis. 
Focal Segmental Glumerolosclerosis  
    Focal segmental glomerulosclerosis (FSGS) is 
a type of chronic nephropathy characterized by 
scattered sclerosis in some glomeruli (focal) in 
which only part of a glomerular capillary tuft is 
affected (segmental) [14-15]. Clinically, FSGS is 
classified as a type of nephrotic syndrome, with a 
massive proteinuria and sclerosis on glomeruli as 
the whole mark [16]. The most sensitive part of 
glomeruli which is affected by pathogenic factors 
in FSGS is podocytes (glomerular visceral 
epithelial cells) [14,17]. 
 It is believed that effacement of foot process in 
podocytes and a defect in slit diagrams 
(Specialized tight junctions between podocytes) 
may cause leaking proteins into urine [18]. 
Damage to podocytes triggers apoptosis and also 
detachment of podocytes from the glomerular 
basement membrane [15,19]. The initial insult to 
the podocyte leads to further damage mediated by 
cytokine release, mechanical stress, and further 
loss of polarity, resulting in 
sclerosis and scarring of the glomerulus [19, 20]. 
Abnormal metabolism of extracellular matrix 
(ECM) proteins, imbalance of sclerotic and anti-
sclerotic factors, disturbed glomerular 
haemodynamics, and oxidative stress-induced 
damage and apoptosis of glomerular cells are 
some suggested mechanisms for FSGS [16].  
Shui et.al in 2008 studied urinary proteome of 
mouse model using 2D gel-based proteomic 
approach to identify urinary proteins at pre-








Table 1. Human urinary biomarkers for focal segmental glumerulosclerosis. 
Protein Name/ID Technique Cases 
Albumin 2DE-MALDI-TOF-MS/ (SDS-PAGE)-IEF 
FSGS-normal [22] 
FSGS(SSNS) [49] 
Alpha-1-antitrypsin 2DE-MALDI-TOF-MS FSGS-normal [22] 
Transferrin SDS-PAGE-IEF FSGS (SSNS) [49] 
IgG SDS-PAGE-IEF FSGS (SRNS) [49] 
β2-microglobulin SDS-PAGE-IEF FSGS (SRNS) [49] 
lysozyme SDS-PAGE-IEF FSGS(SRNS) [49] 
ICAM-1 ELISA FSGS-normal [49] 
TGF-β1 ELISA FSGS-MCD [50] 
ß2-microglobulin SELDI-TOF/MALDI-TOF-MS SSNS-SRNS [51], [52] 
SSNS: Steroid sensitive nephrotic syndrome, SRNS: Steroid resistant nephrotic syndrome, MCD: Minimal change disease. 
 
Table 2. Human urinary biomarkers for IgA nephropathy. 









associated protein 1 
2DE-MALDI-TOF-MS IgAN-normal [31] 
insulin receptor precursor 2DE-MALDI-TOF-MS IgAN-normal [31] 
NADH- ubiquinone 
oxidoreductase 
2DE-MALDI-TOF-MS IgAN-normal [31] 
HLA class I antigen 2DE-MALDI-TOF-MS IgAN-normal [31] 
BTB and kelch 






2DE-MALDI-TOF-MS IgAN-normal [31] 
clathrin heavy chain 2DE-MALDI-TOF-MS IgAN-normal [31] 
extracellular superoxide 
dismutase 
2DE-MALDI-TOF-MS IgAN-normal [31] 
calponin 2DE-MALDI-TOF-MS IgAN-normal [31] 
GRB2-related adaptor 
protein 2 
2DE-MALDI-TOF-MS IgAN-normal [31] 
-cGMP dependent 
phosphodiesterase 
2DE-MALDI-TOF-MS IgAN-normal [31] 
Zinc finger protein 324 2DE-MALDI-TOF-MS IgAN-normal [31] 
Zinc finger protein 155 2DE-MALDI-TOF-MS IgAN-normal [31] 
Albumin 2D-DIGE-MS IgAN-normal [32] 
Transferrin 2D-DIGE-MS IgAN-normal [32] 
α1-Antitrypsin 2D-DIGE-MS IgAN-normal [32] 
β-Globin 2D-DIGE-MS IgAN-normal [32] 
α2-Globin 2D-DIGE-MS IgAN-normal [32] 
Carbonic anhydrase I 2D-DIGE-MS IgAN-normal [32] 
Cystatin C 2D-DIGE-MS IgAN-normal [32] 
Retinol-binding protein 4 2D-DIGE-MS IgAN-normal [32] 
α2-Glycoprotein 1 2D-DIGE-MS IgAN-normal [32] 
α1-Microglobulin 2D-DIGE-MS IgAN-normal [32] 
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Table 3. Human urinary biomarkers for minimal change disease 
Protein name/ID Technique Cases 
IGFBP-1 Urine assay MCD-FSGS [54] 
IGFBP-2 Urine assay MCD-FSGS [54] 
IGFBP-3 Urine assay MCD-FSGS [54] 
Albumin 2DE-MALDI-TOF-MS MCD-normal [22] 
α-1 antitrypsin 2DE-MALDI-TOF-MS MCD-normal [22] 
MCD: Minimal change disease 
 
Table 4. Human urinary biomarkers for Membranous nephropathy 
Protein name/ID Technique Cases 




α-1 antitrypsin 2DE-MALDI-TOF-MS 
MGN-FSGS-DN-SLE [50] /MGN-
normal [22] 
Complement factor B 2DE-MALDI-TOF-MS MGN-FSGS-DN-SLE [56] 
Haptoglobin 2DE-MALDI-TOF-MS MGN-FSGS-DN-SLE [56] 
Hemopexin 2DE-MALDI-TOF-MS MGN-FSGS-DN-SLE [56] 
Orosomucoid 2DE-MALDI-TOF-MS MGN-FSGS-DN-SLE [56] 
Retinol binding protein 2DE-MALDI-TOF-MS MGN-FSGS-DN-SLE [56] 
Transferrin 2DE-MALDI-TOF-MS MGN-FSGS-DN-SLE [56] 
Vitamin D binding protein 2DE-MALDI-TOF-MS MGN-FSGS-DN-SLE [56] 
Zinc α2 glycoprotein 2DE-MALDI-TOF-MS MGN-FSGS-DN-SLE [56] 
MGN: Membranous glomerulonephritis, DN: Diabetic nephropathy, SLE: Systemic lupus erythematosus  
 
They identified 37 urinary proteins by MALDI-
TOF MS showing characteristic patterns of 
dynamic changes along the disease course of 
FSGS which some of them were validated further 
by western blotting. Some of the Proteins with 
potential to affect glomerular sclerosis which 
were reported by this group include: collagen 
fragment, ECM protein 1, Bone morphogenetic 
protein (BMP)-7 and ADAM 32, Whereas  
Kallikrein, kininogen precursor, glutathione S-
transferase, AIF-2, annexin A1 and E-cadherin 
were reported as proteins associated with 
haemodynamic problems, oxidative stress, 
apoptosis and epithelial cell damage.  
Huang et al. in 2009 introduced Rab23 as a 
urinary biomarker for FSGS [21]. They also used 
2D gel and MALDI-TOF MS. Candiano et al. 
studied urine protein patterns from ten children 
with steroid sensitive nephrotic syndrome (SSNS) 
and MCD, seven children with steroid resistant 
nephrotic syndrome (SRNS) and SRNS/FSGS 
and six adolescents and adults with memberanous 
nephropathy Using 2DE followed by MALDI-
TOF MS they identified fragments of albumin and 
alpha-antitrypsin not seen in urine from healthy 
control [22]. Some of the important reported 
biomarkers for FSGS has been shown in table 1. 
IgA nephropathy 
However, IgA nephropathy itself is not consider 
as nephrotic syndrome, we would like to consider 
this glomerular disease here because it could lead 
to nephrotic syndrome eventually.  
Immunoglobulin A nephropathy (IgAN) or 
Berger’s nephropathy [23-24] is the most 
common primary glomerulonephritis worldwide. 
IgAN is characterized by the predominant 
deposition of IgA in the glomerular mesangium. 
Diagnosis of IgA nephropathy is only possible by 
biopsy [25], which reveals the deposition of 
complexes containing polymeric IgA1 in the 
mesangium. Although progressive renal failure 
develops in most patients with IgAN, and 15–
40% of patients with IgAN will eventually 
develop end-stage renal disease, the exact 
etiology of IgAN has yet to be clearly elucidated 
[26–28]. The clinical manifestations of IgAN 
range from asymptomatic microhematuria and 
proteinuria to massive edema with nephrotic 
syndrome, although acute renal failure is 
uncommon [29]. The pathogenic mechanism of 
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IgAN is still not completely understood. Up to 
our knowledge a few number of proteomics study 
have been done regarding IgA nephropathy, 
however they are more than proteomics 
experiments done in other glomerular diseases 
which will be implied in this review. 
Haubitz M et al. in 2005 presented a specific 
urinary polypeptide pattern which could 
distinguish IgA nephropathy from healthy 
controls with a sensitivity of 100% and specificity 
of 90%, and from membranous nephropathy with 
a sensitivity of 77% and a specificity of 100%. 
Sequencing of three of the discriminatory 
polypeptides identified three different fragments  
of serum albumin [30]. In another study, changes 
in the expression of urinary proteins in patients 
with IgAN (n=13) were analyzed using 2-DE and 
comparison of their expression profiles to those of 
normal controls (n=12) [31]. Urinary proteins 
were identified by MALDI-TOF MS. 
Approximately 216 protein spots were detected as 
expressed differentially in IgAN. Among these, 
82 spots were over-expressed, and 134 spots were 
under-expressed as compared to normal controls. 
A total of 84 differentially expressed spots, 
representing 59 different proteins, were finally 
identified in IgAN. Yokota and colleagues [32] 
employed 2D DIGE to define IgAN-specific 
urinary biomarkers. Comparing urinary proteomes 
between patients with IgAN (n=17) and healthy 
controls (n=10), they found increased levels of 
several urine proteins deriving from plasma, 
including: albumin and its degradation products 
(albumin fragments), transferrin, alpha-1-
antitrypsin, and beta globin.  Julian et al. [33] 
applied capillary electrophoresis coupled with MS 
(CE-MS) for diagnosis of renal disease 
characterized by IgA in glomerular 
immunodeposits. They defined the renal damage 
and IgAN patterns in a reference-set of 402 
patients with various renal disorders and 207 
healthy controls. Thongboonkerd and colleagues 
[34] applied microfluidic technology on a chip to 
the proteome profiling of human urine from 31 
healthy controls, four patients with IgAN, and six 
patients with diabetic nephropathy. Comparison 
of urine proteome profile revealed nine different 
spectra in normal and diabetic nephropathy and 
three different spectra in diabetic nephropathy and 
IgAN. Wu et al. [35] used the combination of a 
magnetic bead separation system with MALDI-
TOF-MS to analyze urinary peptides of IgAN 
patients (n=25). They reported a fragment of 
uromodulin (m/z1913,14) as a biomarker which 
distinguish IgAN patients from healthy controls. 
Table 2 shows some of the urinary biomarkers for 
IgAN obtained from human. 
Minimal Change Disease 
   MCD is a glomerular disorder that typically 
leads to the sudden onset of nephrotic-range 
proteinuria. Affected individuals express 
additional features of the nephrotic syndrome 
(NS), including edema of the extremities and face, 
hypoalbuminemia, and hyperlipidemia [36]. MCD 
is the most common cause of NS in children, 
accounting for approximately 90% of cases in 
children aged <10 years and approximately 50% 
of cases in children >10 years [36,37]. In the 
majority of MCD cases, there is no identifiable 
etiology and the diagnosis is idiopathic or primary 
MCD. The relationship between MCD and 
primary FSGS is an active area of debate in 
nephrology. Podocyte injury with foot-process 
effacement is a central feature of both disorders, 
but segmental sclerosis of glomeruli is unique to 
FSGS [38]. MCD is a systemic disorder, possibly 
caused by a circulating factor in the serum, rather 
than a pathological entity restricted to the kidney 
[39]. Although the pathogenesis of minimal 
change glomerulopathy remains unclear, this 
disorder is most likely a consequence of T 
lymphocyte abnormalities. T cells apparently 
produce a product, most likely a lymphokine, that 
increases glomerular permeability to protein. 
When the glomerular permeability factor is 
removed from the kidney, it functions normally. 
Theses factor may have specificity for glomerular 
epithelial cells that results in loss of the charge-
selective barrier of the glomerular basement 
membrane [40].  
Cutler et al. [41] performed 2-DE analysis to 
evaluate changes in urinary proteome profile of 
puromycin aminonucleoside (PAN)  induced 
nephrotoxic rats which showed clinical features 
resembling human minimal change nephropathy 
compared to the controls (n =5 each). At the 
baseline, rat urinary proteins were mostly present 
at low-molecular weight range with two major 
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abundant proteins, a2u-globulin and glial 
fibrillary acidic protein. An administration of 
PAN caused a shift of spot pattern of urinary 
proteins toward the higher molecular weight 
range.These shifted proteins included albumin, 
transferrin, and vitamin D-binding protein. These 
changes were abolished after 672 h of a single 
PAN administration. 
Up to our knowledge there is no proteomic study 
on human urine specimen for minimal change 
disease specifically. However, there are a few 
urinary proteomic studies on comparison several 
types of glomerular diseases including minimal 
change disease in a single study. For instance, 
Weissinger et al. compared urine samples from 
patients with MCD, FSGS, MGN and healthy 
controls to identify peptide expression patterns. 
The classification accuracy was 71.4% for MCD 
and FSGS and 92.9% for MGN [42]. Table 3 
shows some urinary biomarkers for MCD. 
Membranous Nephropathy 
    Membranous nephropathy (MN) remains the 
most common cause of nephrotic syndrome in 
adults age (40-60 years), and it is a leading cause 
of renal failure within the primary 
glomerulonephritis group.[43,44]. Membranous 
glomerulopathy occurs as an idiopathic (primary) 
or secondary disease. Secondary membranous 
glomerulopathy is caused by autoimmune 
diseases (e.g., lupus erythematosus, autoimmune 
thyroiditis), infection (e.g., hepatitis B, hepatitis 
C), drugs (e.g., penicillamine, gold), and 
malignancies (e.g., colon cancer, lung cancer) 
[40]. It is characterized histologically by the 
uniform thickening of the glomerular capillary 
wall on light microscopy [45]. This thickening is 
associated with subepithelial immune complex 
deposits that appear as granular deposits of 
immunoglobulin (Ig) G on immunofluorescence 
and as electron-dense deposits on electron 
microscopy. Symptoms could be proteinuria, 
microscopic hematuria and sometimes 
Hypertension [45-46].  
 Ngai et al. [47] performed serial analysis of 
urinary proteome profile of a rat model of passive 
Heymann nephritis (PHN), which resembles 
human membranous nephropathy. They used 2-
DE technique and also MALDI-TOF and find 37 
proteins which significantly differed in 6 time 
points. Most of these altered proteins have 
functional significance in signaling pathways, 
glomerular trafficking, and controlling the 
glomerular permeability. The other group also 
used 2D-DIGE and MALDI-TOF-MS to find 
differential proteins between urine proteome of 
PHN induced rat and normal cases [48].  
Among the identified proteins, the markedly 
increased level of urine haptoglobin 
(approximately ten-fold increase) was clearly 
confirmed by Western blot analysis and ELISA. 
Table 4 shows some human urinary biomarkers 
reported for MN. 
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